Increasing prevalence of diabetes and upsurge in the number of lifestyle-related conditions such as obesity are augmenting the growth of the global human insulin market. To explore this and many more trends further, Market Research Reports Search Engine (MRRSE) has added a new report titled ‘‘ Global Market Study on Human Insulin: Asia Pacific to Witness fastest Growth by 2020” to its repository. The report, published by Persistence Market Research, covers the present status and forthcoming trends and opportunities in the market for human insulin. The report also offers much information besides in the form of descriptive tables and analytical graphs.
As per this report, the global human insulin market had a total value of US$24,332.6 million in 2014 and is predicted to develop at a CAGR of 12.4% between 2014 and 2020, reaching US$49,197.3 million by 2020. The human insulin market is segmented on the basis of the type of diseases, insulin, and geography. Taking into account the type of human insulin, the market comprises traditional and modern human insulin. Lately, the utilization of human insulin has grown in leaps and bounds because of a rise in the global geriatric population.
As per the Centers for Diseases Control and Prevention (CDC), a U.S.-based national public health establishment, more than 33% kids and teenagers were obese in 2012 in the U.S. This bears out the importance of diabetes and the various conditions associated with it on the human insulin market. In the global perspective, strict administrative prerequisites for medication approval and uneven pricing and constrained access to human insulin in developing nations are controlling the development of the human insulin market.
In this market study, the human insulin market is segmented on the premise of geography into North America, Europe, Asia-Pacific, and Rest of the World (RoW). North America holds the biggest share in the worldwide market for human insulin because of the large aging population in the region and expanding prevalence of diabetes and diabetes-related issues. Asia Pacific is predicted to exhibit a swift growth rate in the worldwide human insulin market in the following five years. China and India are predicted to be the fastest developing human insulin markets within Asia Pacific.
Key organizations profiled in this report include Novo Nordisk A/S, Eli Lilly and Company, Sanofi, Biocon, Tonghua Dongbao Pharmaceutical Co., Ltd., Adocia, Merck & Co., Inc., Pfizer, Inc., Wockhardt, Julphar, Bristol-Myers Squibb Company, GlaxoSmithKline Plc, and Oramed Pharmaceuticals, Inc.